D-0264-2022 Class III Terminated
FDA drug recall D-0264-2022 was initiated by Lupin Pharmaceuticals Inc. on Nov 19, 2021 and is designated Class III. Reason for recall: Subpotent Drug The recall status is terminated (terminated Nov 15, 2022). Affected quantity: 4113 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 8, 2021
- Initiation Date
- Nov 19, 2021
- Termination Date
- Nov 15, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 4113 cartons
Product description
Tydemy (drospirenone, ethinyl estradiol & levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg), packaged in cartons containing 3 wallets of 28 Tablets each, Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United Stated, Manufactured by: Lupin Limited, Pithampur, (M.P.) - 454775, India, 244896, The individual wallet NDC 68180-904-11 and the carton NDC 68180-904-13.
Reason for recall
Subpotent Drug
Distribution pattern
nationwide within the United States
Code information
Lot #: L000784 and L000785, Exp. Date May 2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0264-2022
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026